Precemtabart tocentecan is also being investigated in other oncology indications including gastric cancer, non-small cell lung cancer and pancreatic ductal ...

Following a turbulent funding environment, biotechs are seeking to generate more data earlier to reassure investors.

Ipsen claims that Dysport has become the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.

GSK will discontinue camlipixant’s late-stage RCC programme, though it will continue the drug’s development in two forms of IBS.

Trellis Bioscience has closed a $9m Series C round to support the completion of its ongoing Phase II trial evaluating calpurbatug for chronic PJI.

When the FDA approved Madrigal's Rezdiffra in 2024, it was the first marketed drug ever for MASH, which affects millions of American adults.

Takeda is in the process of submitting an NDA to the FDA for its oral PsO drug. Credit: Jonathan Weiss / Shutterstock.com Takeda has released data for its plaque psoriasis (PsO) pill in key secondary ...

If approved, Keenova's Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.

Teva plans to start a Phase IIb study on TEV-‘408 in vitiligo during the final quarter of 2026 following positive results of a Phase Ib trial.

Kailera Therapeutics’ bet on Hengui Pharma’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA) appears to be paying off following two late-stage wins in obesity and type ...